GSK raises 2025 sales and earnings forecasts with double-digit growth in specialty HIV and cancer drugs, driving shares up by nearly 7%. CEO Emma Walmsley to hand over to Luke Miels, with GSK navigating U.S. tariffs and seeking new medicines to offset revenue declines. U.S. vaccine sales pressure as GSK reports a 15% drop in sales of shingles vaccine, Shingrix, amid negative buzz around vaccines. Incoming CEO Miels aims to hit annual revenue target of over £40 billion by 2031, with GSK expecting revenue to increase by 6-7% and core earnings per share to rise by 10-12%.

Read more at Yahoo Finance: GSK cancer, HIV drug sales lift 2025 outlook in boost for shares